Brief: I-MAB Announces Portfolio Prioritization Of Givastomig As Lead Clinical Program

NovaBridge Biosciences

06/01/2025 12:29

Jan 6 (Reuters) - I-Mab  IMAB.O :
    * I-MAB ANNOUNCES PORTFOLIO PRIORITIZATION OF GIVASTOMIG
(CLDN18.2
X 4-1BB BISPECIFIC ANTIBODY) AS LEAD CLINICAL PROGRAM
    * I-MAB - CASH BALANCE OF $184.4 MILLION AS OF SEPT 2024,
EXPECTED
TO SUPPORT OPERATIONS INTO 2027

Source text:  ID:nPnbZjPkLa 
Further company coverage:  IMAB.O 

 ((Reuters.Brief@thomsonreuters.com))